While no obvious changes were observed in the phosphorylation levels of STAT1 and STAT5, a conclusion may be safely conducted that PMM-172 primarily suppressed STAT3 activation in STAT3-dependent breast cancer cells. This evidence concerns the gene STAT1 and breast carcinoma.